CLCS (Cell Source) EBIT per Share: $-0.08 (TTM As of Dec. 2024)


CLCS Cell Source Inc CLCS
35 GF Score
Price $0.75
View Full Analysis

What is Cell Source EBIT per Share?

Cell Source CLCS -9.64% 35 EBIT per Share is $-0.08 as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

Cell Source's EBIT per Share for the three months ended in Dec. 2024 was $-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cell Source's EBIT per Share or its related term are showing as below:

CLCS's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.45
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Cell Source's EBIT for the three months ended in Dec. 2024 was $-0.20 Mil.

Cell Source  (OTCPK:CLCS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cell Source EBIT per Share Related Terms

Cell Source EBIT per Share Historical Data

* Premium members only.

The historical data trend for Cell Source's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source EBIT per Share Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -0.12 -0.12 -0.11 -0.08

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.03 -0.03 -0.02 -0.01
CLCS
35GF Score
Cell Source Inc CLCS
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cell Source's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBIT per Share(A: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-3.424/41.871
=-0.08

Cell Source's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

EBIT per Share(Q: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.197/43.517
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.08 mean?
Cell Source (CLCS) has a EBIT per Share of $-0.08 as of Dec. 2024. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cell Source and its competitors.
Is Cell Source's EBIT per Share too high?
Cell Source's current EBIT per Share is $-0.08. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's EBIT per Share compare to EDSA and CTXR?
Cell Source's EBIT per Share of $-0.08 can be compared against companies in the Biotechnology industry. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,184 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cell Source and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Source's current EBIT per Share is $-0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current EBIT per Share of $-0.08. The current EBIT per Share is $-0.08. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cell Source (CLCS), the current EBIT per Share is $-0.08 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price